Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
NCT ID: NCT00595309
Last Updated: 2014-05-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
198 participants
INTERVENTIONAL
2007-12-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
NCT00595270
Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
NCT00596102
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
NCT00605085
Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
NCT00604708
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
NCT00776230
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
IC51
IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IC51
IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female healthy subjects aged at least 18 years with written informed consent and either no childbearing potential or negative pregnancy test
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Valneva Austria GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanne Eder
Role: STUDY_DIRECTOR
Valneva Austria GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
Vienna, , Austria
Zentrum für Reisemedizin, Dependance für klinische Studien
Vienna, , Austria
Berliner Zentrum Reise- und Tropenmedizin
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO(R), IC51. Vaccine. 2011 Mar 21;29(14):2607-12. doi: 10.1016/j.vaccine.2011.01.058. Epub 2011 Feb 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IC51-311
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.